Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BEARISH SIGNAL DETECTED
██.█% Sign up free to reveal

Adaptimmune Therapeutics Plc (ADAPY) AI Forecast

Our AI detected a significant signal for Adaptimmune Therapeutics Plc. Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$ADAPY Bearish Signal Full forecast available
Sign Up Free

Adaptimmune Therapeutics Plc (ADAPY) Stock Forecast 2025

Adaptimmune Therapeutics Plc (ADAPY) AI Stock Price Forecast & Investment Analysis

Adaptimmune Therapeutics Plc Stock Price Chart and Technical Analysis

Loading chart...

Adaptimmune Therapeutics Plc (ADAPY) - Comprehensive Stock Analysis & Investment Research

Deep dive into Adaptimmune Therapeutics Plc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 2:55 p.m. (UTC)

Adaptimmune Therapeutics Plc Investment Summary

When evaluating whether Adaptimmune Therapeutics Plc (ADAPY) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Adaptimmune Therapeutics Plc (ADAPY) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $8 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Adaptimmune Therapeutics Plc's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Adaptimmune Therapeutics Plc along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Adaptimmune Therapeutics Plc is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Adaptimmune Therapeutics Plc

Sign Up Free
Corporate Identity

Adaptimmune Therapeutics Plc (Stock Symbol: ADAPY) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the OTC exchange.

Leadership & Workforce

Detailed information about Adaptimmune Therapeutics Plc's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Adaptimmune Therapeutics Plc...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Adaptimmune Therapeutics Plc...

Unlock Full Company Profile

Get complete details about Adaptimmune Therapeutics Plc

Sign Up Free
Revenue & Growth Analysis

Adaptimmune Therapeutics Plc generates annual revenues of $65 million , representing an emerging company in its growth phase.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Adaptimmune Therapeutics Plc...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Adaptimmune Therapeutics Plc...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Adaptimmune Therapeutics Plc...

Unlock Financial Analysis

Get complete financial metrics for Adaptimmune Therapeutics Plc

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Adaptimmune Therapeutics Plc's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Adaptimmune Therapeutics Plc strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Adaptimmune Therapeutics Plc competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-160 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Asset Utilization Efficiency

Asset turnover ratio of 0.50x indicates moderate asset turnover common in capital-intensive industries such as utilities, real estate, or heavy manufacturing. Lower turnover in these sectors is expected due to the significant infrastructure required for operations.

Financial Strength & Leverage

Current ratio of 1.52 indicates adequate liquidity to meet short-term obligations with reasonable cushion. This level balances working capital efficiency with financial safety.

Adaptimmune Therapeutics Plc (ADAPY) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Adaptimmune Therapeutics Plc stock analysis.

Deep dive into Adaptimmune Therapeutics Plc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Adaptimmune Therapeutics Plc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Adaptimmune Therapeutics Plc:

Market Cap $8M
Revenue/Share $0.25
FCF/Share $-0.60
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Adaptimmune Therapeutics Plc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Adaptimmune Therapeutics Plc: An ROE of 87.8% demonstrates excellent shareholder value creation.

ROE 87.8%
ROA -47.7%
ROIC -85.1%
Operating Margin -576.6%
Net Margin -533.8%
EBT Margin -531.8%
Tax Rate -0.4%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Adaptimmune Therapeutics Plc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Adaptimmune Therapeutics Plc: A current ratio of 1.52 shows adequate liquidity.

Current Ratio 1.52x
Quick Ratio 1.29x
D/E Ratio -2.84x
Financial Leverage -1.84x
Interest Coverage -11.6x
Working Capital $27M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Adaptimmune Therapeutics Plc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Adaptimmune Therapeutics Plc: Free cash flow of $-160M indicates cash challenges that need attention.

Operating Cash Flow -$75M
Free Cash Flow -$160M
Capital Spending -$85M
FCF/Sales -245.4%
CapEx/Sales 130.6%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Adaptimmune Therapeutics Plc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Adaptimmune Therapeutics Plc: An asset turnover of 0.50x suggests room for improvement in asset utilization.

Asset Turnover 0.50x
Receivables Turnover 7.0x
Fixed Assets Turnover 2.3x
Days Sales Outstanding 52 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Adaptimmune Therapeutics Plc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Adaptimmune Therapeutics Plc: With annual revenue of $65M, Adaptimmune Therapeutics Plc represents a smaller but potentially high-growth operation.

Income Statement
Total Revenue $65M
Operating Income -$67M
Net Income -$62M
R&D Expense $56M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 78%
Cash & Short-term Investments 26%
Total Liabilities 202%
Short-term Debt 42%
Accounts Receivable 9%
Inventory 11%
Dividend & Shareholder Information
Shares Outstanding 265M
Growth Metrics (YoY)
Net Income Growth -533.8%

Latest Adaptimmune Therapeutics Plc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Adaptimmune Therapeutics Plc (ADAPY) stock price and investment outlook.

📰 Loading...

Adaptimmune Therapeutics Plc Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Adaptimmune Therapeutics Plc against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $157M x 1.8x
ABPO ██% $1M x x
ACOG ██% $179M x 3.1x
ADAPY ██% $8M x x
ADMA ██% $1.94B 11.8x 5.0x
ADPT ██% $3.56B x 16.5x
AGEN ██% $238M 3.7x x
AGTX ██% $800K x x
AIM ██% $7M x 3.3x
ALEC ██% $165M x 15.9x
ALGS ██% $29M x 0.9x
ALLO ██% $628M x 2.3x
ALVO ██% $992M x x
AMGN ██% $200.50B 25.7x 21.8x
APGE ██% $10.05B x x
APTOF ██% $4M x x
ARGX ██% $57.22B x x
ARMP ██% $192M x x
ARTV ██% $492M x 5.6x
ATRA ██% $70M x x
ATYR ██% $49M x 0.8x
AURA ██% $745M x 6.9x
AUTL ██% $405M x 3.7x
AVXL ██% $230M x 1.8x
BCAB ██% $6M x x
BCDA ██% $14M x x
BCLI ██% $11M x x
BCRX ██% $2.38B x x
BDTX ██% $105M x 1.0x
BEAM ██% $2.66B x 2.3x
BIIB ██% $29.53B 21.5x 1.6x
BNTX ██% $23.28B x x
CABA ██% $444M x 4.3x
CADL ██% $722M x 5.2x
CCCC ██% $380M x 1.6x
CELZ ██% $5M x 0.9x
CERO ██% $500K x x
CGEM ██% $1.06B x 2.9x
CGEN ██% $221M 3.1x 2.2x
CGON ██% $6.26B x 5.7x
CGTX ██% $86M x 2.9x
CHRS ██% $221M 1.2x 2.8x
CLDI ██% $2M x 0.4x
CLLS ██% $279M x x
CMPX ██% $382M x 2.1x
CPMV ██% $5M x x
CRDF ██% $65M x 1.9x
CRDL ██% $123M x x
CRIS ██% $9M x 0.7x
CRSP ██% $4.58B x 2.5x
CSBR ██% $83M x 19.5x
CVM ██% $21M x 3.0x
DBVT ██% $820M x 5.1x
DNA ██% $489M x 1.1x
DNLI ██% $3.72B x 4.0x
DTIL ██% $189M x 2.5x
DYAI ██% $44M x x
EDIT ██% $419M x 95.0x
ELUT ██% $40M 0.8x 1.8x
ENGN ██% $127M x 0.5x
ENTX ██% $99M x 9.3x
ENZN ██% $59M x 0.3x
ESLA ██% $32M x x
EVAX ██% $25M x x
EXEL ██% $14.12B 16.9x 7.3x
EXOZ ██% $40M x 26.1x
FATE ██% $293M x 1.6x
FDMT ██% $543M x 1.2x
FENC ██% $351M x 9.3x
GILD ██% $162.53B 17.6x 6.9x
GLUE ██% $1.94B x 3.7x
GNTA ██% $80M x 6.4x
GPLB ██% $260K x x
GRML ██% $30M x 0.6x
HALO ██% $9.58B 27.5x 43.6x
HUMA ██% $172M x 14.8x
IBRX ██% $7.75B x x
IKT ██% $366M x 2.2x
IMA ██% $63M x 0.5x
IMCR ██% $1.81B x 4.6x
IMTX ██% $1.25B x x
IMVT ██% $8.03B x 9.4x
INAB ██% $12M x 0.5x
INKT ██% $50M x x
INMB ██% $46M x 2.3x
INTS ██% $11M x 1.1x
IOVA ██% $2.25B x 3.1x
IPSC ██% $391M x 1.5x
IVVD ██% $172M x 0.9x
JATT ██% $88M x 0.4x
JSPR ██% $24M x 7.1x
KLRS ██% $90M x 1.3x
KOD ██% $2.55B x 22.7x
KRYS ██% $9.64B 42.8x 7.6x
KYMR ██% $9.07B x 5.9x
KYTX ██% $441M x 2.3x
LCTX ██% $267M x 5.0x
LENZ ██% $158M x 0.6x
LIFE ██% $1.87B x 32.2x
LIMN ██% $7M x x
LONA ██% $68M x 1.4x
LXEO ██% $349M x 1.5x
MAZE ██% $1.53B x 4.5x
MESO ██% $2.09B x x
MGTX ██% $986M x x
MGX ██% $46M x 0.3x
MOLN ██% $160M x x
MRNA ██% $22.64B x 3.1x
NBIX ██% $17.52B 26.2x 5.1x
NMRA ██% $281M x 4.0x
NVAX ██% $1.29B x x
OCGN ██% $430M x 74.0x
OTLK ██% $247M x x
PALI ██% $338M x 2.7x
PASG ██% $16M x 1.3x
PCVX ██% $8.03B x 2.7x
PHGE ██% $2M x x
PLUR ██% $19M x x
PLX ██% $189M 12.3x 2.8x
PMCB ██% $6M x 0.2x
PRME ██% $536M x 7.0x
PROK ██% $459M x x
PTHS ██% $96M x 2.7x
QGEN ██% $8.99B x 2.4x
QNCX ██% $18M 2.1x 1.1x
REPL ██% $865M x 5.2x
RGEN ██% $7.76B 151.0x 3.7x
RGNX ██% $656M x 31.1x
RLAY ██% $4.14B x 6.5x
RVMD ██% $37.78B x 25.2x
RXRX ██% $1.60B x 1.6x
SABS ██% $274M x 1.2x
SANA ██% $866M x 7.3x
SCLX ██% $52M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $27M x x
SLDB ██% $804M x 2.2x
SLXN ██% $3M x 8.7x
SNTI ██% $13M x 5.2x
SRRK ██% $5.89B x 21.4x
SRZN ██% $231M x x
STRO ██% $391M x x
TARA ██% $226M x 1.3x
TARS ██% $2.52B x 7.2x
TCRX ██% $52M x 0.5x
TECH ██% $11.23B 102.5x 5.4x
TECX ██% $594M x 2.6x
TIL ██% $48M x 0.4x
TNYA ██% $168M x 1.6x
TSHA ██% $1.67B x 7.9x
TVGN ██% $18M x x
TWST ██% $5.75B x 12.6x
VACH ██% $541M 80.4x x
VALN ██% $488M x x
VCEL ██% $2.30B 107.1x 6.5x
VIR ██% $1.51B x 1.9x
VIVS ██% $2M x 0.4x
VOR ██% $1.03B x x
VXRT ██% $121M 3.3x 1.3x
VYGR ██% $186M x 1.1x
WINT ██% $340K x x
XFOR ██% $376M x 2.2x
ZEOX ██% $14M x 19.4x
ZIVO ██% $19M x x
ZURA ██% $502M x 2.3x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Adaptimmune Therapeutics Plc Stock Forecast

How accurate are Adaptimmune Therapeutics Plc stock predictions?

Our AI model shows a 3% Spearman correlation coefficient for ADAPY predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Adaptimmune Therapeutics Plc stock price forecasts?

Our analysis considers Adaptimmune Therapeutics Plc's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Adaptimmune Therapeutics Plc a good investment in 2025?

Based on our AI analysis, Adaptimmune Therapeutics Plc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Adaptimmune Therapeutics Plc forecasts updated?

Adaptimmune Therapeutics Plc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Adaptimmune Therapeutics Plc?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...